These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21511245)

  • 21. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
    Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
    Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
    Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
    Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience.
    Galuppini F; Pennelli G; Vianello F; Censi S; Zambonin L; Watutantrige-Fernando S; Manso J; Nacamulli D; Lora O; Pelizzo MR; Rugge M; Barollo S; Mian C
    Clin Chem Lab Med; 2016 Sep; 54(9):1531-9. PubMed ID: 26863344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of BRAF mutation on fine needle aspiration biopsy specimens: diagnostic and clinical implications for papillary thyroid cancer.
    Guo F; Hou P; Shi B
    Acta Cytol; 2010; 54(3):291-5. PubMed ID: 20518413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
    Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
    Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
    Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
    Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
    Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomorphological factors and BRAF mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma.
    Chung SY; Lee JS; Lee H; Park SH; Kim SJ; Ryu HS
    Acta Cytol; 2013; 57(3):252-8. PubMed ID: 23636013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterization of 54 cases of false-negative fine-needle aspiration among 1347 papillary thyroid carcinomas.
    Proietti A; Borrelli N; Giannini R; Romani R; Di Coscio G; Quilici F; Rago T; Miccoli P; Vitti P; Basolo F
    Cancer Cytopathol; 2014 Oct; 122(10):751-9. PubMed ID: 24913568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples.
    Dyhdalo K; Macnamara S; Brainard J; Underwood D; Tubbs R; Yang B
    Cancer Cytopathol; 2014 Feb; 122(2):114-22. PubMed ID: 24150898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing RET/PTC in thyroid nodule fine-needle aspirates: the FISH point of view.
    Caria P; Dettori T; Frau DV; Borghero A; Cappai A; Riola A; Lai ML; Boi F; Calò P; Nicolosi A; Mariotti S; Vanni R
    Endocr Relat Cancer; 2013 Aug; 20(4):527-36. PubMed ID: 23722226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules.
    Lee EJ; Song KH; Kim DL; Jang YM; Hwang TS; Kim SK
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):844-50. PubMed ID: 21707687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE; Kim LT; Hackman TG; Dodd LG
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma.
    Zhao L; Dias-Santagata D; Sadow PM; Faquin WC
    Cancer Cytopathol; 2017 May; 125(5):323-331. PubMed ID: 28192645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer.
    Xing M; Tufano RP; Tufaro AP; Basaria S; Ewertz M; Rosenbaum E; Byrne PJ; Wang J; Sidransky D; Ladenson PW
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2867-72. PubMed ID: 15181070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma.
    Collet JF; Lacave R; Hugonin S; Poulot V; Tassart M; Fajac A
    Head Neck; 2016 Jul; 38(7):1017-21. PubMed ID: 26854757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.